AN2 Therapeutics (ANTX)
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company’s initial candidate in...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
AN2 Therapeutics Analyst Rating
View moreForecast & Rating
Aug 14, 2026Price forecast
$9.0066.36%
Forecast & RatingStrong buy
2analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · 2 days ago, 11:46 PM
AN2 Therapeutics director Robin Shane Readnour disposes of 1,108 common shares worth $6,675
- Global Report · Sep 9 at 10:12 AM
The Fringe Playbook: Finding Strategic Leverage in Niche Markets
- Market Beat · Sep 9 at 01:08 AM
Anthem (NASDAQ:ANTX) Director Robin Shane Readnour Sells 6,100 Shares of Stock
- PUBT · Sep 8 at 11:43 PM
AN2 Therapeutics director Robin Shane Readnour reports disposal of common shares worth $97,645.76
- Market Beat · Sep 2 at 11:08 PM
Anthem (NASDAQ:ANTX) Director Margaret Fitzpatrick Purchases 2,098 Shares
- PUBT · Sep 2 at 11:36 PM
AN2 Therapeutics director Margaret M. FitzPatrick acquires 2,098 common shares worth $11,602.94
